GSK plc 13D and 13G filings for Spero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-28 4:30 pm Unchanged | 2025-03-27 | 13D | Spero Therapeutics, Inc. SPRO | GSK plc | 9,190,606 16.400% | 0 (Unchanged) | Filing |
| 2023-01-20 4:08 pm Unchanged | 2022-11-14 | 13D | Spero Therapeutics, Inc. SPRO | GSK plc | 9,190,606 17.750% | 0 (Unchanged) | Filing |
| 2022-11-14 5:02 pm Purchase | 2022-11-07 | 13D | Spero Therapeutics, Inc. SPRO | GSK plc | 9,190,606 19.990% | 7,450,000 (+428.01%) | Filing |
| 2021-09-16 5:27 pm Unchanged | 2021-08-05 | 13D | Spero Therapeutics, Inc. SPRO | GSK plc | 1,740,606 5.400% | 0 (Unchanged) | Filing |
| 2020-12-07 5:08 pm Sale | 2020-11-05 | 13D | Spero Therapeutics, Inc. SPRO | GSK plc | 1,740,606 6.400% | -78,872 (-4.33%) | Filing |